Publications

Found 75 results
Author Title [ Type(Desc)] Year
Filters: First Letter Of Last Name is D  [Clear All Filters]
Journal Article
Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang Z-D, Dupont HL, Garneau P, Harel J et al..  2013.  Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.. Inflamm Bowel Dis. 19(1):141-50.
Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang Z-D, Dupont HL, Garneau P, Harel J et al..  2013.  Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.. Inflamm Bowel Dis. 19(1):141-50.
Lukin DJ, Funez-dePagnier G, Lima S, Lai D, Duenas-Bianchi L, Ahmed W, Jacob V, Battat R, Scherl E, Longman RS.  2021.  No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD.. Clin Gastroenterol Hepatol. 19(11):2312-2314.e3.
Shen T-CDavid, Lebwohl B, Verma H, Kumta N, Tennyson C, Lewis S, Scherl E, Swaminath A, Capiak KM, DiGiacomo D et al..  2012.  Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.. J Clin Neuromuscul Dis. 13(3):137-45.
Decalf J, Fernandes S, Longman R, Ahloulay M, Audat F, Lefrerre F, Rice CM, Pol S, Albert ML.  2007.  Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients.. J Exp Med. 204(10):2423-37.
Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M et al..  2018.  Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 24(11):2461-2467.
Lewis JD, Sandler RS, Brotherton C, Brensinger C, Li H, Kappelman MD, Daniel SG, Bittinger K, Albenberg L, Valentine JF et al..  2021.  A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.. Gastroenterology. 161(3):837-852.e9.
Lewis JD, Sandler RS, Brotherton C, Brensinger C, Li H, Kappelman MD, Daniel SG, Bittinger K, Albenberg L, Valentine JF et al..  2021.  A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.. Gastroenterology. 161(3):837-852.e9.
Lewis JD, Sandler RS, Brotherton C, Brensinger C, Li H, Kappelman MD, Daniel SG, Bittinger K, Albenberg L, Valentine JF et al..  2021.  A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.. Gastroenterology. 161(3):837-852.e9.
Dogan B, Fu J, Zhang S, Scherl EJ, Simpson KW.  2018.  Rifaximin decreases virulence of Crohn's disease-associated Escherichia coli and epithelial inflammatory responses.. J Antibiot (Tokyo). 71(5):485-494.
Kothary V, Scherl EJ, Bosworth B, Jiang Z-D, Dupont HL, Harel J, Simpson KW, Dogan B.  2013.  Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.. Antimicrob Agents Chemother. 57(2):811-7.
Kothary V, Scherl EJ, Bosworth B, Jiang Z-D, Dupont HL, Harel J, Simpson KW, Dogan B.  2013.  Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.. Antimicrob Agents Chemother. 57(2):811-7.
Montrose DC, Scherl EJ, Bosworth BP, Zhou XKathy, Jung B, Dannenberg AJ, Hla T.  2013.  S1P₁ localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity.. J Lipid Res. 54(3):843-51.
Gu W, Wang H, Huang X, Kraiczy J, Singh PNP, Ng C, Dagdeviren S, Houghton S, Pellon-Cardenas O, Lan Y et al..  2021.  SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling.. Cell Stem Cell.
Battat R, Duijvestein M, Casteele NVande, Singh S, Dulai PS, Valasek MA, Mimms L, McFarland J, Hester KD, Renshaw M et al..  2018.  Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.. Clin Gastroenterol Hepatol.
Battat R, Duijvestein M, Casteele NVande, Singh S, Dulai PS, Valasek MA, Mimms L, McFarland J, Hester KD, Renshaw M et al..  2018.  Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.. Clin Gastroenterol Hepatol.
Zhang S, Dogan B, Guo C, Herlekar D, Stewart K, Scherl EJ, Simpson KW.  2020.  Short Chain Fatty Acids Modulate the Growth and Virulence of Pathosymbiont and Host Response.. Antibiotics (Basel). 9(8)
Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS et al..  2019.  Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.. Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
Sedano R, Hogan M, Nguyen TM, Chang J, Zou GY, Macdonald JK, Casteele NVande, Hanzel J, Crowley E, Battat R et al..  2021.  Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis.. J Crohns Colitis.
Sedano R, Hogan M, Nguyen TM, Chang J, Zou GY, Macdonald JK, Casteele NVande, Hanzel J, Crowley E, Battat R et al..  2021.  Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis.. J Crohns Colitis.
Zegarra-Ruiz DF, Kim DV, Norwood K, Kim M, Wu W-JH, Saldana-Morales FB, Hill AA, Majumdar S, Orozco S, Bell R et al..  2021.  Thymic development of gut-microbiota-specific T cells.. Nature. 594(7863):413-417.
Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD.  2015.  Ulcerative Colitis Care Pathway.. Gastroenterology. 149(1):238-45.
Panaccione R, Danese S, Sandborn WJ, O'Brien CD, Zhou Y, Zhang H, Adedokun OJ, Tikhonov I, Targan S, Abreu MT et al..  2020.  Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.. Aliment Pharmacol Ther. 52(11-12):1658-1675.
Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L et al..  2018.  Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.. Am J Gastroenterol. 113(9):1345.
Battat R, Kopylov U, Byer J, Sewitch MJ, Rahme E, Nedjar H, Zelikovic E, Dionne S, Bessissow T, Afif W et al..  2017.  Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational pilot study.. Eur J Gastroenterol Hepatol. 29(12):1361-1367.